Full-Time
Posted on 7/4/2026
Biopharmaceutical company develops medicines and vaccines
$162.9k - $271.5k/yr
No H1B Sponsorship
Phoenixville, PA, USA + 2 more
More locations: Groton, CT, USA | New York, NY, USA
In Person
Onsite 2.5 days per week required.
Bachelor's, Master's, PhD
| , |
See people who can refer or advise you
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.
Company Size
10,001+
Company Stage
IPO
Headquarters
New York City, New York
Founded
1849
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Pfizer reported second-quarter revenue of $15.03 billion and raised its full-year revenue guidance to $60.5 billion to $62.5 billion, up from a previous range of $59.5 billion to $62.5 billion. Adjusted earnings reached 77 cents per share, beating the 68-cent consensus estimate. Revenue growth was led by Eliquis, which rose 19% operationally, and Padcev, which climbed 23%. Paxlovid fell 95% amid lower COVID-19 infection rates, whilst Comirnaty declined 34%. Excluding COVID products, revenues grew 5% operationally. The company announced an additional $2.5 billion in cost savings expected from 2027 through 2029. CFO Dave Denton is departing on 15 August, with Cecile Guegan stepping in as interim CFO. Pfizer shares rose 1.8% to $25.50 in premarket trading.
Pfizer returned $49 billion to shareholders over five years through dividends and buybacks, equal to 34% of its current market value. Despite this substantial cash distribution, the stock delivered a -21% total return whilst the S&P 500 gained 81% over the same period. The pharmaceutical giant generated the payouts from a $63 billion business with a 25% operating margin. Of the total returned, $47 billion came from dividends and $2 billion from share repurchases. Management has affirmed its commitment to maintaining and growing dividends whilst reducing leverage. However, the company faces a "patent cliff" with $14-15 billion in annual revenue at risk from loss of exclusivity. Revenue growth stands at just 1.4% over the last twelve months, raising concerns that heavy payouts reflect fewer high-return reinvestment opportunities as core growth engines slow.
Québec has included Pfizer's PREVNAR 20 vaccine in its publicly funded paediatric pneumococcal immunisation programme as of May 2026. The province is the second in Canada to offer the 20-valent pneumococcal conjugate vaccine for routine infant immunisation, following British Columbia. PREVNAR 20 protects against 20 serotypes of Streptococcus pneumoniae, including seven additional strains associated with high fatality rates, antibiotic resistance, and meningitis. The vaccine is approved in Canada for preventing pneumonia and invasive pneumococcal disease in adults and for active immunisation of infants, children, and adolescents aged six weeks through 17 years. Québec's Comité sur l'immunisation recommends PREVNAR 20 as the vaccine of choice for routine immunisation of infants and children.
Pfizer announced the FDA has accepted for Priority Review a supplemental application for TALZENNA in combination with XTANDI to treat men with HRR gene-altered metastatic castration-sensitive prostate cancer. The application is supported by positive Phase 3 TALAPRO-3 results and existing approvals for later-stage disease. The Priority Review could broaden Pfizer's prostate cancer franchise into an earlier disease setting, potentially expanding the addressable patient population. However, the development does not change the core near-term risk around upcoming loss of exclusivity and pricing pressure. Pfizer's narrative projects $54.9 billion revenue and $9.2 billion earnings by 2029. This implies a 4.6% yearly revenue decline, with earnings rising by about $1.7 billion from $7.5 billion today.
Bluesight has partnered with Pfizer Global Hospital & Biosimilars to integrate RFID-enabled SmartDose medications with the KitCheck inventory management platform. The collaboration allows hospitals using KitCheck to receive medications pre-tagged and encoded at the point of manufacture, eliminating manual tagging work for pharmacy staff. Approximately one-third of US hospitals now use RFID technology to improve inventory management, enhance patient safety, and reduce medication waste. SmartDose medications are tagged during manufacturing using GS1 encoding standards, with each vial undergoing automated verification to ensure tags are readable and correctly encoded. The partnership aims to standardise RFID adoption across hospitals whilst maintaining efficiency and safety benefits. By shifting tagging upstream to manufacturing, the initiative reduces pharmacy workload and allows staff to focus more on patient care.